Wealthcare Advisory Partners LLC Raises Holdings in Novo Nordisk A/S (NYSE:NVO)

Wealthcare Advisory Partners LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 6.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,263 shares of the company’s stock after acquiring an additional 607 shares during the quarter. Wealthcare Advisory Partners LLC’s holdings in Novo Nordisk A/S were worth $1,062,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in NVO. Jennison Associates LLC lifted its holdings in shares of Novo Nordisk A/S by 100.3% in the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after purchasing an additional 11,727,507 shares during the last quarter. Polen Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $718,995,000. FMR LLC grew its position in Novo Nordisk A/S by 122.7% in the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock worth $1,098,328,000 after purchasing an additional 6,654,614 shares during the last quarter. Morgan Stanley raised its stake in shares of Novo Nordisk A/S by 96.5% in the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after buying an additional 4,526,199 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its holdings in shares of Novo Nordisk A/S by 91.7% in the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after buying an additional 4,350,862 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Up 0.0 %

NYSE NVO traded up $0.04 during mid-day trading on Wednesday, reaching $127.33. The stock had a trading volume of 232,606 shares, compared to its average volume of 4,789,627. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The company has a fifty day moving average price of $127.33 and a 200 day moving average price of $113.50. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The stock has a market cap of $571.40 billion, a PE ratio of 43.89, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43.

Analysts Set New Price Targets

Several analysts have recently weighed in on NVO shares. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. Finally, UBS Group initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.